FDA Approval, Biopharma Rebound, Immune Research
Kilder
- STAT: STAT+: FDA expands Bayer lung cancer drug approval
- Raps: Recon: UK unveils recommendations for regulating AI in medicine; FDA halts new enrollment in Biohaven epilepsy trials - RAPS
- App: Bayer's Hyrnuo wins FDA nod as a first-line pill for HER2-mutant lung cancer - Dealroom
- Endpoints: How past Endpoints 11 winners fared as biotech industry rebounded
- BioSpace: August biopharma layoffs impact just over 500, down 90% year over year
- STAT: STAT+: Roivant is one of the savviest dealmakers in biotech. It also has a secret weapon
- GEN: CAR T Manufacturing in Japan Gets Boost from Teijin-Shinshu University Research Collaboration
- GEN: PD-L2 Blockade May Reduce Harmful Aging Cell Buildup - Genetic Engineering and Biotechnology News
- GEN: Chronic Interferon Exposure Linked to Immunosuppression in Cancer - Genetic Engineering and Biotechnology News
- GEN: CAR T Manufacturing in Japan Gets Boost from Teijin-Shinshu University Research Collaboration
- GEN: PD-L2 Blockade May Reduce Harmful Aging Cell Buildup - Genetic Engineering and Biotechnology News
- GEN: Chronic Interferon Exposure Linked to Immunosuppression in Cancer - Genetic Engineering and Biotechnology News
- News-medical: Chronic interferon exposure drives immunosuppression in tumors - News-Medical
- GEN: What 25 Years of Research Have Revealed About 9/11’s Long-Term Health Effects - Genetic Engineering and Biotechnology News
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.